AstraZeneca's Baxdrostat has shown breakthrough results for patients with treatment-resistant hypertension (rHTN) in Phase III trials, significantly lowering blood pressure and showing a favorable safety profile. The drug, which targets the hormone aldosterone, achieved its primary endpoint in both the BaxHTN and Bax24 trials by providing statistically significant and clinically meaningful reductions in both seated and 24-hour ambulatory blood pressure.

Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo.

Bryan Williams, Chair of Medicine at University College London, primary investigator, said: “The landmark results from Bax24 Phase III trial demonstrate that patients with the hardest-to-control hypertension treated with baxdrostat achieved a highly clinically meaningful 14 mmHg placebo-adjusted reduction in 24-hour systolic blood pressure, which could transform treatment practice."

"It's remarkable to see this magnitude of reduction coupled with the fact that just over 70% of baxdrostat patients achieved guideline targets, consistently over 24 hours.”

Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, said: “The Bax24 data demonstrate the significant impact that baxdrostat’s long half-life and highly selective inhibition of aldosterone synthase can have in improving 24-hour and overnight blood pressure for patients with resistant hypertension."

"Patients with elevated night-time blood pressure are especially vulnerable to cardiovascular events, including heart attack and stroke. Together with the results from BaxHTN, these findings demonstrate the potential of baxdrostat to redefine what is possible for the millions of patients whose hypertension remains uncontrolled despite current therapies.”